Table 1.
Antiobesity drugs on the market.
| Drug | Mechanism | Approval | Side effect |
|---|---|---|---|
| Phentermine | Sympathomimetics agent | 1959 | Palpitations, elevated blood pressure |
| Topiramate/Phentermin | Sympathomimetic/anticonvulsant | 2012 | Depression, suicidal ideation |
| Cathin hydrochloride | Sympathomimetics agent | 1975 | Tachycardia, increase in blood pressure |
| Sibutramine | Sympathomimetics agent | 1997 | Non-fatal myocardial infarction and stroke |
| Fenfluramine | Sympathomimetics agent | 1973 | Cardiac valvular insufficiency |
| Rimonabant | CB1 receptor blocker | 2006 | Depression, suicidal ideation |
| Bupropion/Naltrexone | Opioid receptor antagonist/dopamine and noradrenaline reuptake inhibitor | 2014 | Seizures, palpitations, transient blood pressure elevations |
| Orlistat | Pancreatic lipase inhibitor | 1999 | Gastrointestinal symptoms, liver injury |
| Liraglutide | GLP-1R agonists | 2014 | Nausea/vomiting, diarrhea, gallstones |
| Semaglutide | GLP-1R agonists | 2021 | Nausea/vomiting, diarrhea |